Work

A phase 1, open-label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of PF-07799933 (ARRY-440) as a single agent and in combination therapy in participants 16 years and older with advanced solid tumors with BRAF alterations.

Year: 2023

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2023.41.16_suppl.tps3164

Authors: J. Thaddeus Thaddeus Beck, Meredith McKean, Shirish M. Gadgeel, Daniel W. Bowles, Rizwan Haq, Rona Yaeger, Matthew H. Taylor, Arnab K. Maity, Stefanie Drescher, Colleen Oliver, Ann Marie Huelskamp, Gang Feng, Keren Sturtz

Institutions: Highlands Oncology Group, Sarah Cannon, Tennessee Oncology, Henry Ford Health, Harvard University, Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, Providence Portland Medical Center, Pfizer (United States)

Language: English

Topic: Melanoma and MAPK Pathways

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Pfizer

OpenAlex ID: W4379283226

Cites:

Cited by: 6

Related to: 10